Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Indibulin
Sponsor: Alaunos Therapeutics
Collaborators: Memorial Sloan Kettering Cancer Center